6-[1-aza-2-(dimethylamino)vinyl]-1-methyl-3-propyl-1,3-dihydropyrimidine-2,4-dione | 1055300-49-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 6-[1-aza-2-(dimethylamino)vinyl]-1-methyl-3-propyl-1,3-dihydropyrimidine-2,4-dione
• 英文别名: N,N-dimethyl-N'-(3-methyl-2,6-dioxo-1-propylpyrimidin-4-yl)methanimidamide
• CAS: 1055300-49-6
• 化学式: C₁₁H₁₈N₄O₂
• 分子量: 238.29
• InChiKey: OEUCMWDVAXAROU-XYOKQWHBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  56.2
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  6-[1-aza-2-(dimethylamino)vinyl]-1-methyl-3-propyl-1,3-dihydropyrimidine-2,4-dione 在 ammonium hydroxide 、 sodium dithionite 、 溶剂黄146 、 sodium nitrite 作用下， 以 甲醇 、 乙醇 为溶剂， 反应 13.5h， 生成 5,6-二氨基-1-甲基-3-丙基嘧啶-2,4-二酮
  参考文献：
  名称：

  Synthesis and lipid-lowering evaluation of 3-methyl-1H-purine-2,6-dione derivatives as potent and orally available anti-obesity agents

  摘要：

  Obesity accompanied with metabolic disorder is often complicated with a strong link of dyslipidemia and insulin resistance, whose indicator is the excess accumulation of triglycerides (TG) in cells. Consideration the idea of lipid-lowering and improving insulin resistance, 34 novel compounds by combination the xanthine scaffold with the chain of Rosiglitazone have been synthesized. Among them, several compounds showed efficiency on reducing TG in 3T3-L1 adipoctyes, and 11c exhibited the most optimal capacity in lipid-lowering and improving obese clinical symptoms in DIO mice. Furthermore, the hydrochloride of 11c (11c center dot HCl) showed excellent bioavailability, 58.94%, over 2 folds than that (28.03%) of 11c, and the anti-obesity effect of 11c center dot HCl at 50 mg/kg dose was better than that of Metjormin at 150 mg/kg dose in DIO mice, almost reversed HFD to a normal level. Thus, 11c center dot HCl might be a potent and orally available anti-obesity agent via alleviating the obese clinical symptoms, body fat, improving serum parameters and insulin resistance and TG clearance in liver. (c) 2014 Published by Elsevier Masson SAS.

  DOI：

  10.1016/j.ejmech.2014.09.094
• 作为产物：
  描述：

  6-氨基-1-甲基尿嘧啶 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 0.08h， 生成 6-[1-aza-2-(dimethylamino)vinyl]-1-methyl-3-propyl-1,3-dihydropyrimidine-2,4-dione
  参考文献：
  名称：

  Synthesis and lipid-lowering evaluation of 3-methyl-1H-purine-2,6-dione derivatives as potent and orally available anti-obesity agents

  摘要：

  Obesity accompanied with metabolic disorder is often complicated with a strong link of dyslipidemia and insulin resistance, whose indicator is the excess accumulation of triglycerides (TG) in cells. Consideration the idea of lipid-lowering and improving insulin resistance, 34 novel compounds by combination the xanthine scaffold with the chain of Rosiglitazone have been synthesized. Among them, several compounds showed efficiency on reducing TG in 3T3-L1 adipoctyes, and 11c exhibited the most optimal capacity in lipid-lowering and improving obese clinical symptoms in DIO mice. Furthermore, the hydrochloride of 11c (11c center dot HCl) showed excellent bioavailability, 58.94%, over 2 folds than that (28.03%) of 11c, and the anti-obesity effect of 11c center dot HCl at 50 mg/kg dose was better than that of Metjormin at 150 mg/kg dose in DIO mice, almost reversed HFD to a normal level. Thus, 11c center dot HCl might be a potent and orally available anti-obesity agent via alleviating the obese clinical symptoms, body fat, improving serum parameters and insulin resistance and TG clearance in liver. (c) 2014 Published by Elsevier Masson SAS.

  DOI：

  10.1016/j.ejmech.2014.09.094

文献信息

• Method of wound healing using A2B adenosine receptor antagonists
  申请人：Zeng Dewan

  公开号：US20060058322A1

  公开（公告）日：2006-03-16

  The present invention relates to methods of wound healing using A 2B adenosine receptor antagonists. The invention also relates to methods for the preparation of such compounds, and to pharmaceutical compositions containing them.

  本发明涉及使用A2B腺苷受体拮抗剂进行伤口愈合的方法。该发明还涉及制备此类化合物的方法，以及包含它们的药物组合物。
• A2B adenosine receptor antagonists
  申请人：——

  公开号：US20040176399A1

  公开（公告）日：2004-09-09

  Disclosed are processes for the synthesis of novel compounds that are A 2B adenosine receptor antagonists, useful for treating various disease states, including asthma and diarrhea.

  披露的是合成新型化合物的过程，这些化合物是A2B腺苷受体拮抗剂，可用于治疗包括哮喘和腹泻在内的各种疾病状态。
• METHOD OF PREVENTING AND TREATING HEPATIC DISEASE USING A2B ADENOSINE RECEPTOR ANTAGONISTS
  申请人：Zeng Dewan

  公开号：US20070219221A1

  公开（公告）日：2007-09-20

  The invention is related to methods of preventing and treating hepatic fibrosis using A 2B adenosine receptor antagonists and utility in the treatment and prevention of liver damage caused by alcohol abuse, surgical intervention, viral hepatitis, the ingestion of hepatotoxic drugs, or other hepatic diseases. The invention also relates to pharmaceutical compositions for use in the method.

  本发明涉及使用A2B腺苷受体拮抗剂预防和治疗肝纤维化的方法，以及在治疗和预防因酒精滥用、外科手术干预、病毒性肝炎、摄入肝毒性药物或其他肝脏疾病引起的肝脏损伤中的用途。本发明还涉及用于该方法的药物组合物。
• [EN] XANTHINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS<br/>[FR] DERIVES DE XANTHINE SERVANT D'ANTAGONISTES DU RECEPTEUR DE L'ADENOSINE A2B
  申请人：CV THERAPEUTICS INC

  公开号：WO2004106337A1

  公开（公告）日：2004-12-09

  Disclosed are compounds that are A2B adenosine receptor antagonists, useful for treating various disease states, including asthma and diarrhea.

  揭示了一种A2B腺苷受体拮抗剂化合物，可用于治疗包括哮喘和腹泻在内的各种疾病状态。
• A2B Adenosine receptor antagonists
  申请人：Kalla Rao

  公开号：US20050261316A1

  公开（公告）日：2005-11-24

  Disclosed are novel compounds that are A 2B adenosine receptor antagonists, useful for treating various disease states, including asthma and diarrhea.

  揭示了一种新颖的化合物，它们是A2B腺苷受体拮抗剂，可用于治疗包括哮喘和腹泻在内的各种疾病状态。